Patents by Inventor Jerry Todd Thompson

Jerry Todd Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunotoxin fusion proteins and means for expression thereof
    Patent number: 8217158
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: July 10, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF
    Publication number: 20110086416
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: March 5, 2010
    Publication date: April 14, 2011
    Applicant: The Government of the US, as Represented by the Secretary, Department of Health and Human Services
    Inventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxin with in vivo T cell suppressant activity and methods of use
    Patent number: 7517527
    Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: April 14, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Shenglin Ma
  • IMMUNOTOXIN WITH IN VIVO T CELL SUPPRESSANT ACTIVITY AND METHODS OF USE
    Publication number: 20030157093
    Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
    Type: Application
    Filed: September 3, 1999
    Publication date: August 21, 2003
    Inventors: DAVID M. NEVILLE, JR., JOSHUA E. SCHARFF, JERRY TODD THOMPSON, HUAIZHONG HU, SHENGLIN MA